Tag Archives: Novantrone

Combination Therapy in Multiple Sclerosis

The treatment of multiple sclerosis (MS) has been revolutionalized over the past decade. Just 12 years ago, multiple sclerosis was not considered a treatable neurologic illness and our therapeutic armamentarium consisted largely of symptomatic therapies and corticosteroids to treat acute exacerbations. Currently, there are five drugs [the three beta interferons (IFNs) (Avonex®, Betaseron®, and Rebif®),… Read More »

Mitoxantrone in Multiple Sclerosis

Mitoxantrone () was developed in the 1970s and is an antineoplastic agent. It is an anthracenedione derivative related to the anthracyclins doxorubicine and daunorubicine. It interacts with topoisomerase-2, stabilizes its cleavable complex with DNA, thus prevents the ligation of DNA strands, and consecutively delays the cell-cycle progression. Mitoxantrone is used to effectively treat malignancies such… Read More »

Glatiramer Acetate (Copaxone)

The past 15 years have seen a revolution in our understanding and management of many neurologic diseases, including multiple sclerosis (MS). The US Food and Drug Administration (FDA) approved the first of the interferon (IFN) preparations, IFNβ-1b (Betaseron®) for multiple sclerosis in 1993, followed by glatiramer acetate (Glatiramer Acetate, Copaxone®) in 1995, intramuscular IFNβ-1a (Avonex®)… Read More »

Acute Treatment: Mitoxantrone

Several class II and III studies suggest a role for mitoxantrone in treatment of worsening relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis. mitoxantrone has been approved for treatment of worsening RRMS, secondary progressive MS, and progressive relapsing multiple sclerosis. Mitoxantrone is an antineoplastic agent that has been used for prostate cancer and nonlymphocytic leukemia… Read More »